Host: HEK293 cells • AA: 171-424 • Tag: N-terminal His
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Prominin-1/CD133 Splice Variant s7 EC2 Domain (rat, recombinant)

Item No. 43696

Product Insert (PDF)
Technical Information
Synonyms
  • Cluster of Differentiation 133
  • PROM1
Purity
≥90% estimated by SDS-PAGE
Endotoxin Testing
<1.0 EU per ug of the protein as determined by the LAL method
Source
Recombinant rat N-terminal His-tagged CD133 splice variant s7 EC2 domain expressed in HEK293 cells
Amino Acids
171-424
Lyophilized from sterile PBS, pH 7.4
Host
HEK293 cells
UniProt Accession №
Q7TSL4
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    CD133, also known as prominin-1, is a five-transmembrane domain glycoprotein and stem cell marker.1 It is composed of an N-terminal extracellular domain (EC1) and two extracellular loops (EC2 and EC3), which are linked via two intracellular loops (IC1 and IC2), and a C-terminal cytoplasmic domain (IC3). CD133 localizes to membrane protrusions and undergoes extensive alternative splicing, where each splice variant is expressed in a tissue-dependent manner.1,2,3 In addition to its expression in stem cells, CD133 is also expressed in some differentiated epithelial cells, such as in the proximal tubules of the kidneys, epididymal tract, and various glands, and differentiated nonepithelial cells, including photoreceptor cells.1 It is involved in regulating membrane architecture of microvilli and cilia, stem cell transit, autophagy, interactions with lipid rafts, and intercellular communication, among other processes. CD133 is commonly used as an antigen to isolate stem cells, including cancer stem cells, from biological samples.1,4 Mutations in PROM1, the gene encoding CD133, are associated with macular degeneration.5 Cayman’s Prominin-1/CD133 Splice Variant s7 EC2 Domain (rat, recombinant) protein consists of 274 amino acids and has a calculated molecular weight of 30.9 kDa. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is approximately 47 to 57 kDa.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Pleskač, P., Fargeas, C.A., Veselska, R., et alEmerging roles of prominin-1 (CD133) in the dynamics of plasma membrane architecture and cell signaling pathways in health and disease. Cell. Mol. Biol. Lett. 29(1), 41 (2024).

    2. Fargeas, C.A., Huttner, W.B., and Corbeil, D. Nomenclature of prominin-1 (CD133) splice variants - an update. Tissue Antigens 69(6), 602-606 (2007).

    3. Shmelkov, S.V., Jun, L., St Clair, R., et alAlternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103(6), 2055-2061 (2004).

    4. Haraguchi, N., Utsunomiya, T., Inoue, H., et alCharacterization of a side population of cancer cells from human gastrointestinal system. Stem Cells (2005).

    5. Yang, Z., Chen, Y., Lillo, C., et alMutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J. Clin. Invest. 118(8), 2908-2916 (2008).